PRESS RELEASE published on 03/05/2025 at 15:52, 1 month 21 days ago Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors Oncodesign Precision Medicine appoints Christophe Thurieau, Executive Director Research at Servier, as an independent member of the Board of Directors for a four-year term. Thurieau brings over 35 years of healthcare expertise to OPM Board Of Directors Healthcare Christophe Thurieau Oncodesign Precision Medicine Servier
BRIEF published on 03/05/2025 at 15:52, 1 month 21 days ago Christophe Thurieau rejoint le Conseil d'Administration d'Oncodesign Precision Medicine Biotechnologie Conseil D'administration Nomination Christophe Thurieau Oncodesign Precision Medicine
BRIEF published on 03/05/2025 at 15:52, 1 month 21 days ago Christophe Thurieau joins the Board of Directors of Oncodesign Precision Medicine Board Of Directors Biotechnology Appointment Christophe Thurieau Oncodesign Precision Medicine
PRESS RELEASE published on 03/05/2025 at 15:47, 1 month 21 days ago Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors Nomination de Christophe Thurieau en tant qu’administrateur indépendant du Conseil d’Administration d’OPM. Christophe Thurieau, expert en Recherche et Développement Pharmaceutique, rejoindra OPM pour un mandat de 4 ans Biopharmaceutique Médecine De Précision Administrateur Indépendant OPM Christophe Thurieau
BRIEF published on 10/15/2024 at 08:05, 6 months 11 days ago OPM-101 Phase 1 Trial Results Presented at UEG Week 2024 Ulcerative Colitis Phase 1 Trial UEG Week 2024 OPM-101 Safety Profile
BRIEF published on 10/15/2024 at 08:05, 6 months 11 days ago Résultats de l'essai de phase 1 OPM-101 présentés à l'UEG Week 2024 Rectocolite Hémorragique Semaine UEG 2024 OPM-101 Essai De Phase 1 Profil De Sécurité
PRESS RELEASE published on 10/15/2024 at 08:00, 6 months 11 days ago Inside Information / Other news releases OPM presents safety & efficacy data on OPM-101, a novel RIPK2 kinase inhibitor, in healthy volunteers at UEG Week 2024 conference, targeting IBD treatment Precision Medicine UEG Week 2024 OPM-101 RIPK2 Kinase Inhibitor IBD Treatment
Published on 04/26/2025 at 02:00, 1 day 4 hours ago Battery X Metals Announces Strategic Agreement to Advance Artificial Intelligence-Driven Exploration of Critical Battery Metals in Nevada, USA
Published on 04/25/2025 at 23:30, 1 day 6 hours ago AIML Innovations Announces Departure of Tim Daniels from Board of Directors
Published on 04/25/2025 at 23:01, 1 day 7 hours ago Medicure Reports Financial Results for Quarter and Year Ended December 31, 2024
Published on 04/25/2025 at 23:00, 1 day 7 hours ago AIML Optimizes Quantum Sciences Acquisition to Drive Growth & Strategic Focus
Published on 04/25/2025 at 22:15, 1 day 8 hours ago Grande Portage Resources Announces Extension of Expiry Date for Warrants
Published on 04/25/2025 at 22:47, 1 day 7 hours ago DEAG achieves new revenue level in “transformation year” 2024 – Strategic investments and strong start to the year create basis for future sustainable growth
Published on 04/25/2025 at 20:30, 1 day 9 hours ago EQS-Adhoc: Nagarro SE: Confirms 2024 guidance and dividend, postpones publication for full-year results
Published on 04/25/2025 at 18:44, 1 day 11 hours ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 04/25/2025 at 18:31, 1 day 11 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/25/2025 at 18:30, 1 day 11 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/26/2025 at 07:00, 23 hours 27 minutes ago Groupe DLSI - Chiffre d'affaires 1er trimestre 2025
Published on 04/25/2025 at 18:05, 1 day 12 hours ago Louis Hachette Group - Chiffre d'affaires du 1e trimestre 2025